Varian Medical Systems Supports Third Stage Study On Lung Cancer Radiosurgery

Varian Medical Systems, Inc. VAR revealed it was supporting a third stage clinical study comparing outcomes of a radiosurgery versus surgical resection for the early-stage, operable non-small cell lung cancer treatment. The company said it was called as ‘the Stablemates trial' and randomized the trial.

The company pointed out the trial involves 34 institutions and 258 patients currently that were led by co-chairs Hiran Fernando, Boston Medical Center, and Robert Timmerman of University of Texas Southwestern Medical Center.

Varian Medical Systems, President, Kolleen Kennedy, said "Varian believes in supporting high quality clinical research. This clinical trial presents the opportunity to advance radiation oncology and enhance the standard of patient care by giving clinicians a noninvasive treatment option in determining the appropriate therapy for patients."

Timmerman added, "In addition to a potentially longer survival rate, SAbR may benefit some lung cancer patients by offering them a noninvasive, outpatient treatment option that is easier to tolerate and that doesn't interfere greatly with their normal, everyday living activities."

The stock shed 0.4 percent on Friday closing.